nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-D4E0F858·Framework v5.9·Pipeline v0.4·Evaluated 08 Oct 2026·OECD: 3.2 Clinical medicine·Subfield: Physiology·Basis: Full text·Type: Laboratory experiment

Post-mortem evidence of pathogenic angiogenesis and abnormal vascular function in early Alzheimer's disease.

Asby et al.Asby, Fisher, Jackson et al.·2025·Brain : a journal of neurology·10.1093/brain/awaf394 ↗

Primary claim

The present data provide evidence of widespread cerebral hypoperfusion associated with pathogenic angiogenesis and vascular remodelling in AD.

Tentative · pathogenic framing outruns cross-sectional proxy-marker associations and is affected by directional reporting inconsistencies
In brief

A broad regional post-mortem study strengthens vascular associations in early Alzheimer’s disease, but its causal framing exceeds what cross-sectional biomarkers can establish.

ReliabilityCaveats4 of 4 checks completeRead the 2 entries ↓
Fragile — the claim's weakest requirement is that it works through the path described. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.
Abstract

Cerebral hypoperfusion and blood-brain barrier (BBB) leakiness are pathological features of Alzheimer's disease (AD). To understand their relationship to the distribution and progression of Alzheimer's disease neuropathologic change (ADNC), we analysed associations between biochemical markers and mediators of cerebral hypoperfusion and BBB leakiness, and amyloid-β (Aβ) and hyperphosphorylated tau, in multiple brain regions at different Braak tangle stages (BS). We studied the frontal, temporal, parietal, entorhinal, calcarine and cingulate cortex, putamen and trigonal white matter from eight controls with low pathology (BS0-II), 17 brains with early-stage/intermediate AD pathology (BSIII-IV) and 11 late-stage AD cases (BSV-VI), from the South West Dementia Brain Bank and the London Neurodegenerative Diseases Brain Bank. We excluded cases with widespread moderate-severe arteriolosclerosis, macroscopic infarcts or foci of haemorrhage, Lewy body pathology or other neurodegenerative pathology. ELISAs were used to measure the myelin-associated glycoprotein:proteolipid protein-1 ratio (MAG:PLP1), an index of ante-mortem cerebral perfusion, and fibrinogen levels, to assess BBB leakiness. Also by ELISA, we measured vascular endothelial growth factor-A (VEGF-A), upregulated in cerebral ischaemia; endothelin-1 (EDN1), a mediator of vasoconstriction; CD31, an endothelial marker; platelet-derived growth factor-β (PDGFRβ), a pericyte marker; and Aβ1-40, Aβ1-42 and ptau-231 concentrations. In the temporal cortex from a subset of cases, 55 angiogenesis-related proteins were assayed using a multiplex profiler assay. MAG:PLP1 was lower in BSIII-IV than BS0-II in all brain regions. VEGF-A, EDN1 and CD31 concentrations were highest in BSIII-IV in most regions and correlated inversely with MAG:PLP1. EDN1 level correlated strongly with Aβ1-42 concentration in low-pathology controls. Angiogenesis-related protein assays showed elevated levels of endoglin (CD105), a marker of neoangiogenesis, in BSIII-IV, coinciding with altered expression of several angiogenic mediators. The PDGFRβ:CD31 ratio, a marker of pericyte content adjusted for vessel density, was lower in BSIII-IV than BS0-II and correlated positively with MAG:PLP1 and inversely with Aβ1-42. BBB leakiness, evidenced by elevated fibrinogen in brain tissue homogenates, was highest in BSV-VI in most brain regions and correlated with VEGF-A, CD31 and ptau-231 concentrations. The present data provide evidence of widespread cerebral hypoperfusion associated with pathogenic angiogenesis and vascular remodelling in AD. The study highlights a complex and dynamic temporal relationship, beginning in early-stage AD, between mediators of cerebrovascular dysfunction and the regional spread of Aβ and tau pathology. The study also identifies several therapeutic targets, including EDN1 and VEGF-A signalling, with the potential to limit cerebrovascular damage in early AD.

Key Claims

Primary finding · Tentative

The present data provide evidence of widespread cerebral hypoperfusion associated with pathogenic angiogenesis and vascular remodelling in AD.

Fragile — the claim's weakest requirement is that it works through the path described. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.

pathogenic framing outruns cross-sectional proxy-marker associations and is affected by directional reporting inconsistencies

Abstract, final paragraph
Quote verified
Secondary · Tentative

MAG:PLP1 was lower in BSIII–IV than BS0–II controls in all cortical regions studied, as well as the putamen.

regional group differences support the scoped result, but the broader abstract wording incorrectly includes all regions

Results, Fig. 1
Quote verified
Secondary · Supported

EDN1 correlated strongly with Aβ1–42 in the BS0–II group in almost all cortical regions.

reported regional correlations are consistent, though based on eight controls and extensive uncorrected testing

Results, “EDN1 correlates with Aβ1–42 in low-pathology controls”; Fig. 4
Quote verified
Secondary · Supported

PDGFRβ:CD31 was lower in BSIII–IV than BS0–II in all grey matter regions.

the regional group comparison is reported consistently, although interpretation as pericyte loss remains indirect

Results, “PDGFRβ levels are lower…”; Fig. 6A
Quote verified
Secondary · Supported

BBB leakiness, evidenced by elevated fibrinogen in brain tissue homogenates, was highest in BSV-VI in most brain regions and correlated with VEGF-A, CD31 and ptau-231 concentrations.

regional associations support the direction, but bulk-homogenate fibrinogen is an indirect BBB-leakiness proxy

Abstract; Results, Fig. 7
Quote verified

Derived from the full evaluation — not a separate score.

Strengths · Limitations

Strengths

#contribution

Broad regional mapping across disease stages

The study measures vascular and pathological markers across six cortical regions, putamen and trigonal white matter in three Braak-stage groups, extending earlier single-region work.

↳ Methods, Study Cohort; Results, Figs. 1–7

#methodological rigour

Detailed biochemical assay procedures

ELISA methods identify assay sources, dilution procedures, duplicate measurements and total-protein normalization, with carry-over samples used to monitor plate variation.

↳ Methods, Brain Tissue Homogenization through Statistical Analyses

#positioning

Limitations explicitly tied to interpretation

The Discussion acknowledges the small control group, absence of cell-type resolution, unavailable vascular comorbidities and inability of post-mortem correlations to prove causality.

↳ Discussion, limitations paragraph

Limitations

#reporting

Central correlation directions are contradictory

The text labels CD31–MAG:PLP1 as inverse despite positive coefficients and PDGFRβ:CD31–MAG:PLP1 as positive despite negative coefficients. These inconsistencies affect relationships used in the vascular-remodelling interpretation.

↳ Results, Figs. 3B and 6B

#methodological rigour

Causal conclusions exceed study design

The Conclusion describes Aβ1-42–EDN1-induced hypoperfusion and VEGF-A-induced remodelling, although the study is cross-sectional and the limitations state that causality cannot be proven.

↳ Discussion, limitations paragraph; Conclusion

#methodological rigour

Multiplicity and small subsets limit inference

Numerous regional correlations lack a stated global correction, while the 55-protein profiler uses only n=3, n=3 and n=4. This makes nominally significant findings vulnerable to instability and multiplicity.

↳ Methods, Angiogenic Proteomic Profiler and Statistical Analyses; Results, Fig. 5

Does this match your read? Add your assessment ↓

Nabu Commentary

The multi-region design and documented ELISA procedures support a useful extension of an established vascular-biomarker programme. The score is held in the middle band because extensive regional testing, the n=3/3/4 angiogenesis subset and two-bank Z-score combination create meaningful inferential uncertainty. More importantly, the Conclusion converts cross-sectional associations into induced causal pathways despite an explicit statement that the design cannot prove causality. Contradictory correlation directions in Figs. 3B and 6B also require correction before the vascular-remodelling interpretation can be read reliably.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
2.9±0.2

Contribution
3.1

The study makes a genuine but incremental contribution by extending earlier regional findings across eight regions and adding endoglin profiling and vessel-density-adjusted PDGFRβ analysis. The small angiogenesis subset limits the weight of its most novel component.

Introduction, final paragraph; Results, Figs. 1, 5 and 6

“We studied multiple cortical brain regions and the putamen and trigonal white matter”

Methodological Rigour
2.8

The cohort, exclusions, duplicate ELISAs, catalogue information and plate carry-over checks are described, but extensive testing, a small n=3/3/4 profiler subset and two-bank Z-score combination introduce uncertainty. Cross-sectional associations are also used to support causal pathway language, while bulk fibrinogen is treated as BBB leakiness without addressing intravascular content.

Methods, Study Cohort, Angiogenic Proteomic Profiler and Statistical Analyses; Conclusion

“associations and correlations may provide circumstantial evidence in support of hypotheses but cannot prove causality”

Reporting
3.1

The manuscript is logically organized, but causal terms such as “induced” and “pathogenic” materially strengthen the central interpretation beyond the observational design. Directional and significance-reporting inconsistencies further hinder accurate reading of specific results.

Abstract; Results, Figs. 3B and 6B; Conclusion

“Aβ1-42-EDN1-induced cerebral hypoperfusion, VEGF-A-induced vascular remodelling”

Positioning
2.8

The Discussion engages clinical perfusion studies, vascular transcriptomics and mechanistic literature, and it includes a substantive limitations paragraph. Positioning is capped because the Conclusion restates causal contributors after explicitly acknowledging that the post-mortem associations cannot prove causality.

Discussion, literature synthesis, limitations paragraph and Conclusion

“cannot prove causality”

Reliability

Caveats4 of 4 checks


Results checkNoted
  • The present data provide evidence of widespread cerebral hypoperfusion associated with pathogenic angiogenesis and vascular remodelling in AD: "Concentrations of CD31, a marker of endothelial cells, were raised in BSIII–IV in most brain regions and correlated inversely with MAG:PLP1 and positively with VEGF-A." (Discussion, CD31 and endoglin paragraph) vs "CD31 correlated inversely with MAG:PLP1 in the temporal cortex (r = 0.62, P < 0.001) and trigonal white matter (r = 0.53, P < 0.01) and weakly in the calcarine, frontal and parietal cortex (Fig. 3B)." (Results, widespread markers of cerebrovascular dysfunction, CD31 correlation paragraph). The printed temporal and trigonal correlation coefficients, 0.62 and 0.53, are positive and therefore contradict the stated inverse association. → Not supported by the paper's own data
  • The present data provide evidence of widespread cerebral hypoperfusion associated with pathogenic angiogenesis and vascular remodelling in AD: "The PDGFRβ:CD31 ratio, a marker of pericyte content adjusted for vessel density, was lower in BSIII-IV than BS0-II and correlated positively with MAG:PLP1 and inversely with Aβ1-42." (Abstract) vs "PDGFRβ:CD31 correlated positively with MAG:PLP1 in the frontal (r = −0.69, P < 0.01) and temporal cortex (r = −0.60, P < 0.001), and more weakly in the calcarine cortex and putamen (Fig. 6B)." (Results, PDGFRβ levels are lower in early-stage AD). The printed frontal and temporal correlation coefficients, −0.69 and −0.60, are negative and therefore contradict the stated positive association. → Not supported by the paper's own data
  • EDN1 correlated strongly with Aβ1–42 in the BS0–II group in almost all cortical regions: "Elevated EDN1 and reduced PDGFRβ were both strongly related to Aβ42 concentration in early AD." (Discussion, opening paragraph) vs "VEGF-A, EDN1 and CD31 did not correlate with pathological markers across the entire cohort but analysis within groups stratified according to BS stage revealed that EDN1 correlated strongly with Aβ1–42 in the BS0–II group in almost all cortical regions:" (Results, EDN1 correlates with Aβ1–42 in low-pathology controls). The Discussion assigns the strong EDN1–Aβ42 relationship to early AD, whereas the Results explicitly assign it to BS0–II low-pathology controls rather than the BSIII–IV early-stage/intermediate group. → Not supported by the paper's own data
Reporting and transparencyClean

No existing reporting or conduct concern supports a retained finding after excluding unavailable supplementary material and ungrounded reporting-error allegations.

Ethics approval: declared · Data availability: declared · Code availability: not stated

Reference IntegrityNoted

50 references in manuscript 50 of 50 checkable references found in an index

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Neurological · Alzheimer's disease and other dementias
Type of advanceEmpirical
Route to useSuggested
AdvanceAdvances
BeneficiariesLarge
CitationsToo early
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessFoundational
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

The evidence is observational post-mortem tissue measurements and correlations, which the authors state cannot prove causality, so nothing has been shown working in an intervention.

From the paper
“The study also identifies several therapeutic targets, including EDN1 and VEGF-A signalling, with the potential to limit cerebrovascular damage in early AD.”

The paper names a possible real-world use of its findings, namely therapeutic targets, but does not specify who would act on them or in what setting.

Pathway

Drug developers could act on the identified EDN1 and VEGF-A signalling targets to develop treatments limiting cerebrovascular damage in early Alzheimer's disease.

Barrier

The findings are associative post-mortem data that cannot establish causality, so causal validation in living patients and intervention trials is still needed.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. Comparing amyloid immunotherapy with cholinesterase inhibitors for Alzheimer's disease

    2026 · Neurology and psychiatry

    Evidence Score
    3.4±0.2
    Reliability
    No concerns
  2. Divergent toxicity mechanisms of amyloid-beta aggregates arising from a single aggregation reaction

    2026 · Basic medicine

    Primary claim

    aggregates enriched during the growth phase downregulated homeostatic microglial markers and induced TLR4-mediated microglial activation, cytokine production, and complement activation, leading to synaptic engulfment and severe disruption of neuronal activity

    Tentative
    Evidence Score
    2.8±0.2
    Reliability
    Caveats
  3. A timeline of tau-mediated synaptotoxicity

    2026 · Basic medicine

    Primary claim

    even brief tau oligomer exposure induces lasting bipartite synapse dysfunction and presenting a timeline of progressive pre- and post-synaptic degeneration.

    Tentative
    Evidence Score
    3.2±0.2
    Reliability
    No concerns

How the rubric works →